IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 9051-9061

  Jin, Lingjing ^a   Pan, Lizhen ^a   Liu, Wuchao ^a   Guo, Yan ^a   Zheng, Yuguo ^b   Guan, Qiang ^a   Nie, Zhiyu ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b China National Center for Biotechnology Development   (China)

Author keywords

Botulinum toxin; Insulin like growth factor 1; Muscle strength; Muscle specific receptor tyrosine kinase

Indexed keywords

BOTULINUM TOXIN A; NEUROMODULIN; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; RECOMBINANT ANTIBODY; RECOMBINANT INSULIN-LIKE GROWTH FACTOR 1 ANTIBODY; SOMATOMEDIN BINDING PROTEIN 5; UNCLASSIFIED DRUG; ANTIBODY; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR; MESSENGER RNA; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME SPECIFICITY; LEG MUSCLE; MALE; MUSCLE FUNCTION; MUSCLE INNERVATION; MUSCLE STRENGTH; NONHUMAN; PARALYSIS; PROTEIN DETERMINATION; RAT; SINGLE DRUG DOSE; ANIMAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INJECTION; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

RATTUS;

ANIMALS; ANTIBODIES; BOTULINUM TOXINS; GAP-43 PROTEIN; INJECTIONS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCLE STRENGTH; PARALYSIS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLINERGIC; RNA, MESSENGER; TIME FACTORS;

EID: 84876915442     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14059051     Document Type: Article

References (33)

1. Jahn, R.; Niemann, H. Molecular mechanisms of clostridial neurotoxins. Ann. N. Y. Acad. Sci. 1994, 733, 245-255.
2. Scott, A.B. Botulinum toxin injection of eye muscles to correct strabismus. Trans. Am. Ophthalmol. Soc. 1981, 79, 734-770.
3. Jankovic, J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 2004, 75, 951-957.
4. Dolly, J.O.; Aoki, K.R. The structure and mode of action of different botulinum toxins. Eur. J. Neurol. 2006, 13, 1-9.
5. Pellizzari, R.; Rossetto, O.; Schiavo, G.; Montecucco, C. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos. Trans. R. Soc. Lond. B 1999, 354, 259-268.
6. De Paiva, A.; Meunier, F.A.; Molqo, J.; Aoki, K.R.; Dolly, J.O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA 1999, 96, 3200-3205.
7. Harrison, A.R.; Anderson, B.C.; Thompson, L.V.; McLoon, L.K. Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin treated adult extraocular muscles. Invest. Ophthalmol. Vis. Sci. 2007, 48, 3594-3601.
8. Shen, J.; Ma, J.; Lee, C.; Smith, B.P.; Smith, T.L.; Tan, K.H.; Koman, L.A. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats. J. Orthop. Res. 2006, 24, 1128-1135.
9. Delbono, O. Neural control of aging skeletal muscle. Aging Cell 2003, 2, 21-29.
10. Musaro, A.; McCullaqh, K.; Paul, A.; Houghton, L.; Dobrowolny, G.; Molinaro, M.; Barton, E.R.; Sweeney, H.L.; Rosenthal, N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001, 27, 195-200.
11. Caroni, P.; Becker, M. The downregulation of growth-associated proteins in motoneurons at the onset of synapse elimination is controlled by muscle activity and IGF1. J. Neurosci. 1992, 12, 3849-3861.
12. Apel, P.J.; Ma, J.; Callahan, M.; Northam, C.N.; Alton, T.B.; Sonntag, W.E.; Li, Z. Effect of locally delivered IGF-1 on nerve regeneration during aging: An experimental study in rats. Muscle Nerve 2010, 41, 335-341.
13. Rind, H.B.; von Bartheld, C.S. Target-derived cardiotrophin-1 and insulin-like growth factor-I promote neurite growth and survival of developing oculomotor neurons. Mol. Cell Neurosci. 2002, 19, 58-71.
14. Caroni, P.; Schneider, C. Signaling by insulin-like growth factors in paralyzed skeletal muscle: Rapid induction of IGFI expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J. Neurosci. 1994, 14, 3378-3388.
15. Harrison, A.R.; Berbos, Z.; Zaldivar, R.A.; Anderson, B.C.; Semmer, M.; Lee, M.S.; McLoon, L.K. Modulating neuromuscular junction density changes in botulinum toxin-Treated orbicularis oculi muscle. Invest. Ophthalmol. Vis. Sci. 2011, 52, 982-986.
16. Hu, G.C.; Chuang, Y.C.; Liu, J.P.; Chien, K.L.; Chen, Y.M.; Chen, Y.F. Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: A randomized trial comparing two injection volumes. Clin. Rehabil. 2009, 23, 64-71.
17. Detrembleur, C.; Leieune, T.M.; Renders, A.; van den Bergh, P.Y. Botulinum toxin and short-term electrical stimulation in the treatment of equinus in cerebral palsy. Mov. Disord. 2002, 17, 162-169.
18. Dressler, D. Botulinum toxin for treatment of dystonia. Eur. J. Neurol. 2010, 17, 88-96.
19. Lebeda, F.J.; Cer, R.Z.; Stephens, R.M.; Mudunuri, U. Temporal characteristics of botulinum neurotoxin therapy. Expert Rev. Neurother. 2010, 10, 93-103.
20. Dressler, D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov. Disord. 2004, 19, S92-S100.
21. Rha, D.W.; Yang, E.J.; Chung, H.I.; Kim, H.B.; Park, C.; Park, E.S. Is electrical stimulation beneficial for improving the paralytic effect of botulinum toxin type A in children with spastic diplegic cerebral palsy? Yonsei Med. J. 2008, 49, 545-552.
22. Keith, F.; John, C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins (Basel) 2010, 2, 2795-2815.
23. Shiotani, A.; O'Malley, B.W., Jr.; Coleman, M.E.; Alila, H.W.; Flint, P.W. Reinnervation of motor endplates and increased muscle fiber size after human insulin-like growth factor I gene transfer into the paralyzed larynx. Hum. Gene. Ther. 1998, 9, 2039-2047.
24. Streppel, M.; Azzolin, N.; Dohm, S.; Guntinas-Lichius, O.; Haas, C.; Grothe, C.; Wevers, A.; Neiss, W.F.; Angelov, D.N. Focal application of neutralizing antibodies to soluble neurotrophic factors reduces collateral axonal branching after peripheral nerve lesion. Eur. J. Neurosci. 2002, 15, 1327-1342.
25. Benowitz, L.I.; Routtenberg, A. GAP-43: An intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997, 20, 84-91.
26. Strochlic, L.; Cartaud, A.; Cartaud, J. The synaptic muscle-specific kinase (MuSK) complex: New partners, new functions. Bioessays 2005, 27, 1129-1135.
27. Kim, N.; Burden, S.J. MuSK controls where motor axons grow and form synapses. Nat. Neurosci. 2008, 11, 19-27.
28. Yang, X.; Arber, S.; William, C.; Li, L.; Tanabe, Y.; Jessell, T.M.; Birchmeier, C.; Burden, S.J. Patterning of muscle acetylcholine receptor gene expression in the absence of motor innervation. Neuron 2001, 30, 399-410.
29. Witzemann, V. Development of the neuromuscular junction. Cell Tissue Res. 2006, 326, 263-271.
30. James, P.L.; Jones, S.B.; Busby, W.H., Jr.; Clemmons, D.R.; Rotwein, P. A highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed during myoblast differentiation. J. Biol. Chem. 1993, 268, 22305-22312.
31. Mukherjee, A.; Wilson, E.M.; Rotwein, P. Insulin-like growth factor (IGF) binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions. Mol. Endocrinol. 2008, 22, 206-215.
32. Bach, L.A. The insulin-like growth factor system: Towards clinical applications. Clin. Biochem. Rev. 2004, 25, 155-164.
33. Pickett, A.; O'Keeffe, R.; Judge, A.; Dodd, S. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon 2008, 52, 455-464.